Skip to content

Search Results

No Matching Results

    Recently Viewed


      HomeLatest newsWhat you need to know about Johnson & Johnson’s 2023 third-quarter earnings
      A cartoon displaying multiple different types of charts and graphs

      What you need to know about Johnson & Johnson’s 2023 third-quarter earnings

      Check out this infographic breakdown of the company’s third-quarter 2023 performance, with key highlights from its Innovative Medicine and MedTech businesses.

      Share Article
      share to

      This morning, Johnson & Johnson shared its third-quarter 2023 performance.

      Since its founding in 1886, the company has grown to become the world’s largest, most diversified healthcare products company, with more than 130,000 employees across the globe working every day to help change the trajectory of health for humanity.

      This Q3 2023 infographic further highlights how Johnson & Johnson continues to progress its long-term operational and financial priorities and deliver value to its stakeholders.

      “We are confident that Johnson & Johnson’s strong performance through the first nine months of this year will continue, and as a result, we have increased our guidance for 2023,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. “The strength of our business, the promise of our Innovative Medicine and MedTech pipelines, and our 130,000 colleagues around the world position us well for long-term growth and significant value creation for shareholders.”

      For more details about the company’s 2023 third-quarter results, and to read a message from Chairman of the Board and Chief Executive Officer Joaquin Duato, here’s an infographic that highlights key stats.

      Johnson & Johnson 2023 Q3 Earnings infographic

      Johnson & Johnson’s 2023 3rd-Quarter Earnings

      Read the earnings press release, which includes full financial data for the third quarter of 2023.

      Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

      More from Johnson & Johnson

      What’s the difference between IBS and IBD?

      These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.

      What is IL-23?

      This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat autoimmune conditions such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.

      What is a gene mutation?

      Experts aren’t sure why, but sometimes changes in DNA can trigger cancer to grow and spread. For DNA Day learn all about gene mutations—and Johnson & Johnson’s work developing new therapies to target these specific types of cancer.
      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.